To assess the efficacy of our proposed therapeutic strategies in either STAT3-high or -low patient cohorts, we first treated both STAT3-stratified GBM cells with DMSO solvent, 0.5 μM AZD1480 with/without TMZ at 20–200 μM range (Fig. 5a). This evidence concerns the gene STAT3 and glioblastoma.